Disc Medicine Inc. announced positive initial data from the Phase 2 RALLY-MF clinical trial evaluating DISC-0974 for the treatment of anemia in patients with myelofibrosis. Results were presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting. The data showed that DISC-0974 led to substantial reductions in hepcidin and increased iron levels, resulting in clinically meaningful improvements in anemia across various patient groups, regardless of baseline transfusion status or concomitant JAK inhibitor therapy. The treatment was generally well-tolerated, with diarrhea and urinary tract infections being the only adverse events considered related to DISC-0974 and reported in two or more subjects. Additional data from the study are expected to be shared in the second half of 2026.